Krystal Biotech annual ebitda
2019
2020
2021
2022
Krystal Biotech EBITDA Growth & History (KRYS)
Krystal Biotech's calculated EBITDA was −$141.1M for fiscal 2022.
View full Krystal Biotech company overviewKrystal Biotech annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | −$141.1M | −$75.6M | — |
| 2021 | 2021-12-31 | −$65.5M | −$34.4M | — |
| 2020 | 2020-12-31 | −$31.1M | −$10.2M | — |
| 2019 | 2019-12-31 | −$21.0M | — | — |
Krystal Biotech quarterly ebitda
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | −$25.2M | $5.3M | — |
| Q2 2023 | 2023-06-30 | −$37.0M | −$9.2M | — |
| Q1 2023 | 2023-03-31 | −$48.1M | $1.1M | — |
| Q4 2022 | 2022-12-31 | −$33.7M | −$12.6M | — |
| Q3 2022 | 2022-09-30 | −$30.5M | −$15.6M | — |
| Q2 2022 | 2022-06-30 | −$27.8M | −$12.1M | — |
| Q1 2022 | 2022-03-31 | −$49.2M | −$35.4M | — |
| Q4 2021 | 2021-12-31 | −$21.1M | −$11.2M | — |
| Q3 2021 | 2021-09-30 | −$14.9M | −$5.7M | — |
| Q2 2021 | 2021-06-30 | −$15.7M | −$9.2M | — |
| Q1 2021 | 2021-03-31 | −$13.8M | −$8.3M | — |
| Q4 2020 | 2020-12-31 | −$9.9M | −$4.9M | — |
| Q3 2020 | 2020-09-30 | −$9.2M | — | — |
| Q2 2020 | 2020-06-30 | −$6.5M | — | — |
| Q1 2020 | 2020-03-31 | −$5.5M | — | — |
| Q3 2019 | 2019-09-30 | −$5.0M | — | — |
Krystal Biotech ebitda trends
Across the available reported history, Krystal Biotech's ebitda decreased from −$65.5M to −$141.1M, a change of −$75.6M. The latest reported quarter, Q3 2023, shows −$25.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Krystal Biotech filings at SEC.gov ↗